Genentech Presents Positive Data from Trials on Crenezumab and Gantenerumab for Alzheimer’s

Genentech Presents Positive Data from Trials on Crenezumab and Gantenerumab for Alzheimer’s
The latest clinical data from Genentech on crenezumab and gantenerumab demonstrate the investigational therapies' potential to reduce amyloid aggregates in Alzheimer’s disease patients. Trial results were discussed in several presentations at the 2018 Alzheimer's Association International Conference (AAIC), recently held in Chicago. “The range of data that Roche and Genentech are presenting at AAIC is a testament to our commitment to bring new treatments to help the many millions of people living with Alzheimer’s disease,” Sandra Horning, MD, chief medical officer and head of global product development at Roche, said in a press release. One of the hallmarks of Alzheimer’s disease is the formation of protein plaques and tangles between nerve cells. These are made of beta-amyloid fragments that stick together and accumulate between nerve cells, disrupting their function.

Crenezumab

Crenezumab is an investigational monoclonal antibody first discovered by AC Immune and now being developed by Genentech, a Roche<
Subscribe or to access all post and page content.

One comment

  1. DANTE MARCIANI says:

    What are the effects on the cognitive functions of those receiving these antibodies? Can they compare with aducanumab and BAN2401 effects on cognitive functions? Plaque reduction is meaningless without an improvement of cognitive functions. Moreover, all of the failed antibodies and vaccines have reduced plaque without any benefits on the mental state of the patients.

Leave a Comment

Your email address will not be published. Required fields are marked *